|
Paul Desjourdy, President and Chief Executive Officer of Symbollon Pharmaceuticals (SYMBA) discusses Symbollon’s recent completion of private placements to accredited investors, as well as their clinical trials for IoGen for treatment of pain caused by breast disease. Sam Hopkins editor of Orbus Investor & Energy and Capital discusses his recent journeys to the former Soviet Republic of Georgia where he feels the next war for oil will take place.
|
